U.S. equities saw sharp declines across multiple sectors on Tuesday, as macroeconomic concerns, sector-specific pressures, and weak earnings reports triggered a broad selloff. Leading the list of the biggest stock declines today were names like Global-E Online Ltd., Forge Global Holdings, and Cellebrite DI Ltd., each posting double-digit losses. Investors pulled out of technology, healthcare, and consumer discretionary stocks, as the latest GDP contraction figures and tariff escalations stoked recessionary fears.
Market-wide risk aversion was also driven by anxiety over renewed U.S.–China trade tensions, hawkish Federal Reserve commentary, and institutional rebalancing ahead of key earnings reports.
Why Did Global-E Online (GLBE) Stock Fall?
Global-E Online Ltd. (NASDAQ: GLBE) dropped 19.13% to close at $34.28, with volume soaring to 9.13 million shares, more than four times its three-month average. Despite a strong 43.65% gain over the past year, the cross-border e-commerce firm came under pressure due to slowing European consumer spending and concerns over increased digital service taxation in the EU. With a market cap of $5.81 billion and no listed P/E ratio, investors are reassessing the company’s valuation amid rising global compliance costs.
What Caused Forge Global (FRGE) to Drop?
Forge Global Holdings, Inc. (NYSE: FRGE) fell 14.00% to $15.30, hitting new lows for the year. Trading volume was light at 209,000, yet institutional sentiment appeared bearish. The company, which enables secondary market trading of pre-IPO equity, faces headwinds from reduced venture capital activity and fewer unicorn exits. With a market cap below $200 million and no earnings yet, analysts have warned that tighter capital markets may constrain Forge’s growth outlook.
Why Did Cellebrite DI (CLBT) Stock Drop Sharply?
Cellebrite DI Ltd. (NASDAQ: CLBT) declined 11.48%, finishing at $17.81. The digital forensics firm, despite a 75.41% 52-week gain, suffered from investor profit-taking. There are also growing concerns about data privacy regulations and geopolitical scrutiny of surveillance software providers. Trading volume exceeded 5.3 million shares, more than triple its average, reflecting elevated sell-side activity.
What Sent Legend Biotech (LEGN) Shares Lower?
Legend Biotech Corporation (NASDAQ: LEGN) fell 10.55% to $27.80, as volume spiked to 4.18 million shares. Despite progress on its CAR-T pipeline, weak earnings guidance and intensifying competition in the cell therapy space led to a reassessment of growth potential. The company, with a $5.72 billion market cap, has now lost 32.08% over the past year.
Why Was Loar Holdings (LOAR) Down Over 10%?
Loar Holdings Inc. (NYSE: LOAR) declined 10.45% to $83.41, with volume surging to 2.45 million, nearly quadrupling its norm. Though the aerospace component supplier had posted 86.28% gains over the past 12 months, its extreme valuation (P/E of 347.54) prompted sharp reversals amid sector-wide profit-booking. Institutional flows showed significant exit activity as high-multiple industrial names were rotated out of.
What Caused the Selloff in Ubiquiti (UI)?
Ubiquiti Inc. (NYSE: UI) dropped 7.63% to $421.83. The networking hardware firm lost over $2.2 billion in market value as volume doubled. Investors expressed concerns about increased input costs, slower enterprise IT spending, and narrowing operating margins. Its trailing P/E ratio of 46.41 remains elevated despite global cost pressures.
Why Did Summit Therapeutics (SMMT) Slide?
Summit Therapeutics Inc. (NASDAQ: SMMT) lost 7.56% to close at $22.75. The clinical-stage biotech stock, despite a 448.11% gain over the last year, is experiencing increased skepticism over near-term catalysts. With no earnings, sentiment is being driven largely by momentum, and any slowdown in pipeline news is translating into volatility.
What Led to the Decline in Bio-Techne (TECH) Stock?
Bio-Techne Corporation (NASDAQ: TECH) was down 7.27% to $47.86. The life sciences tools company is down 38.19% over 12 months as laboratory research spending contracts. At a P/E of 57.66, the stock remains expensive compared to peers, and institutional outflows suggest reallocations toward more defensive sectors.
Why Did Klaviyo (KVYO) Shares Plunge?
Klaviyo, Inc. (NYSE: KVYO) declined 7.12% to $34.83. Volume surged to 4.86 million, double its average. The email marketing automation firm is under pressure due to slowing SaaS spending and increasing customer churn. While the stock remains 51.21% above its 52-week low, profit-taking and sector rotation away from growth SaaS are weighing.
What Caused the Drop in American Eagle Outfitters (AEO)?
American Eagle Outfitters, Inc. (NYSE: AEO) declined 6.45% to $11.90, its lowest close in months. Investors were disappointed with recent footfall trends, and broader retail weakness pushed shares down further. The company’s low P/E of 7.58 has not been enough to attract buyers amid a 47.39% YTD decline.
Why Did Bio-Rad Laboratories (BIO) Fall?
Bio-Rad Laboratories, Inc. (NYSE: BIO) lost 6.35%, ending at $237.07. Analysts cited weak revenue guidance and delays in diagnostic segment growth as catalysts. The firm’s $6.36 billion market cap and lack of profitability metrics have kept institutional investors cautious.
Why Was Aurora Innovation (AUR) Under Pressure?
Aurora Innovation, Inc. (NASDAQ: AUR) slid 6.28% to $6.86. Even after a 150.68% gain this past year, the AV tech company saw investor pullback as regulatory pressures mount, and commercial rollouts remain years away.
What Dragged Down Alcon Inc. (ALC)?
Alcon Inc. (NYSE: ALC) fell 6.11% to $87.24, following weak surgical equipment sales in Asia-Pacific. Volume surged above 5.6 million, and its $43.36 billion market cap came under threat as investors questioned growth sustainability amid FX headwinds.
Why Did Root Inc. (ROOT) Stock Fall?
Root, Inc. (NASDAQ: ROOT) dropped 6.02% to $141.20. Despite being up 144.81% YTD, the insurtech firm saw analyst downgrades on valuation concerns and uncertain underwriting profitability. Short interest in the name has also spiked.
What Caused the Drop in Tempus AI (TEM)?
Tempus AI, Inc. (NASDAQ: TEM) lost 5.99% to settle at $64.78. Despite riding the AI wave in diagnostics, investors remain wary about its cash burn rate and market competition. Institutional sentiment remains neutral-to-cautious.
Why Did Medpace Holdings (MEDP) Slide?
Medpace Holdings, Inc. (NASDAQ: MEDP) dropped 5.94% to $291.73. The CRO firm has a P/E of 22.29, and although profitable, investor concerns over biotech funding constraints weighed on the stock.
What Pushed Revvity (RVTY) Lower?
Revvity, Inc. (NYSE: RVTY) fell 5.88% to $91.02. The diversified diagnostics player has struggled with margin compression and is down 9.88% over the past year. Analysts expect further weakness unless core growth rebounds.
Why Did IQVIA (IQV) and ICON (ICLR) Fall in Tandem?
IQVIA Holdings Inc. (NYSE: IQV) fell 5.88% to $141.82, while ICON Public Limited Company (NASDAQ: ICLR) dropped equally to $132.23. Both CROs are facing lower biotech client spend and margin risk from pricing pressure. ICON is now down over 56% YoY, while IQVIA has lost 35.52%.
What Triggered the Selloff in Moderna (MRNA)?
Moderna, Inc. (NASDAQ: MRNA) dropped 5.77% to $24.02. With no COVID tailwinds and a weak near-term vaccine pipeline, sentiment remains bearish. The stock is down 80.25% from its highs.
Why Did AbbVie (ABBV) Lose Over $10 Billion in Market Cap?
AbbVie Inc. (NYSE: ABBV) lost 5.62% to close at $177.44. Investors responded negatively to updated guidance on Humira revenue erosion and relatively slow adoption of successor products. Its P/E of 80.65 suggests high expectations that may not be met.
What Caused the Fall in QuidelOrtho (QDEL), CAE (CAE), and Meritage Homes (MTH)?
QuidelOrtho Corporation (NASDAQ: QDEL) dropped 5.52% to $33.55, as COVID-related revenues continue to collapse. CAE Inc. (NYSE: CAE) fell 5.46% to $24.57, impacted by defence budget uncertainty. Meritage Homes Corporation (NYSE: MTH) fell 5.43% to $67.21, reacting to rising mortgage rates and soft housing demand.
Why Did Warby Parker (WRBY) Fall?
Warby Parker Inc. (NYSE: WRBY) lost 5.41% to close at $17.48, as investor expectations reset following weak Q1 results. The direct-to-consumer eyewear brand continues to face marketing inefficiencies and margin headwinds.
Institutional Sentiment and What’s Next
Across the board, institutional selling was evident, with growth funds and hedge funds leading the exodus from overbought or richly valued names. The weakness was exacerbated by short interest increases, particularly in biotech and software names. Some mutual funds have begun reallocating from volatile mid-caps to large-cap defensives and dividend-yielding energy plays.
Looking ahead, markets await the next set of retail sales, housing starts, and Fed minutes, all of which could impact positioning. Sector rotation may continue if macro headwinds persist, particularly in rate-sensitive and consumer-facing names.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
